Skin & hair

When Hives Need Xolair or Cyclosporine

Save

Reaching the point where antihistamines and add-on medication haven't controlled chronic hives is frustrating, but it also means a defined next tier of treatment. This piece compares omalizumab and cyclosporine directly — what evidence supports each, how they work, what monitoring each requires, and how a specialist actually chooses between them.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

The Short Answer: Different Evidence, Different Roles

Omalizumab and cyclosporine are both used for chronic hives that haven't responded to a full trial of antihistamines — including antihistamine up-dosing and add-on medication — but they sit in different positions on the treatment ladder because of how differently they're studied and used. Omalizumab is FDA-approved specifically for chronic idiopathic urticaria and has randomized, placebo-controlled trial data behind it, which is why guidelines and most clinicians reach for it first among the targeted options 1. Cyclosporine is an older immunosuppressant, originally developed for other conditions, that's used off-label here — effective for some people, but without the same volume of urticaria-specific trial evidence, and with a different set of monitoring requirements that come from suppressing the immune system more broadly rather than targeting the specific antibody involved in hives.

What the Trial Evidence Shows for Omalizumab

A randomized, placebo-controlled trial in people with chronic idiopathic or spontaneous urticaria that hadn't responded to H1-antihistamines found that omalizumab significantly improved itch and hive symptoms compared with placebo 1. Omalizumab works by binding circulating IgE antibody, reducing the amount available to trigger the mast-cell activation that produces hives and swelling — a targeted mechanism rather than a broad immune suppressant. It's given as a periodic injection rather than a daily pill, which is a meaningful practical difference for some people weighing the two options, though it means committing to a clinic visit on a set schedule rather than a medication taken at home.

Where Cyclosporine Fits, and Why the Evidence Looks Different

Cyclosporine calms chronic hives by suppressing T-cell activity more broadly, a different and less targeted mechanism than omalizumab's antibody-specific approach, and it's taken as a daily oral medication rather than an injection. It's been used for treatment-resistant chronic urticaria for decades, well before omalizumab existed, and many clinicians have real experience with it — but because it isn't FDA-approved specifically for urticaria and doesn't have the same body of large randomized trials behind it for this use, it's generally positioned as an alternative for people who can't access or tolerate omalizumab, rather than a co-equal first choice. That doesn't mean it's a weaker medication broadly — cyclosporine has decades of use in other immune conditions — it means the urticaria-specific evidence base is thinner, which is part of why guidelines lean toward omalizumab first when both are reasonable options.

Monitoring and Practical Differences

The two options ask different things of a person day to day. Omalizumab requires periodic injection visits and monitoring for the small chance of a delayed allergic reaction after dosing, but doesn't require routine blood draws to track organ function the way an immunosuppressant does. Cyclosporine requires regular blood pressure checks and lab monitoring of kidney function, since suppressing the immune system this broadly carries more systemic effects to watch for over the course of treatment. Neither is inherently more convenient — a periodic clinic-based injection suits some schedules better, while an at-home pill with regular lab monitoring suits others — but the difference in ongoing monitoring is a real, practical factor in the decision. Pregnancy planning is another practical factor clinicians weigh, since the safety data and typical guidance differ meaningfully between an injectable antibody therapy and an oral immunosuppressant, which is a conversation worth having directly rather than assuming either option is automatically off the table.

Does Either Treat the Same Kind of Hives?

The trial evidence for omalizumab specifically covers chronic idiopathic or spontaneous urticaria — hives with no identifiable trigger — rather than chronic inducible urticaria, the related category where hives are set off by a specific physical trigger like cold, pressure, or exercise 1. That distinction matters when a clinician is deciding whether either targeted therapy is even the right category of treatment, since chronic inducible urticaria sometimes calls for a different approach centered on identifying and managing the trigger itself, alongside the same antihistamine escalation used for spontaneous hives.

How Guidelines Sequence These Options

Chronic urticaria guideline recommendations describe a structured, stepwise approach: second-generation antihistamines first, then up-dosing, then add-on medication, and only after all of that has been given a real trial does the conversation move to a targeted therapy like omalizumab or an immunosuppressant option 2. Antihistamines not working for hives is usually the starting point of this whole conversation, not the end of it, and the urticaria treatment algorithm exists precisely so that people aren't skipped ahead to a more intensive treatment before the simpler steps have had a fair chance. Reaching this stage means hives have been reasonably classified as antihistamine-refractory, a specific clinical category with its own defined next moves rather than a sign that nothing more can be done.

Making the Choice With a Specialist

The decision between omalizumab and cyclosporine isn't something to work out from a comparison alone — it depends on a person's full health history, including kidney function and blood pressure, insurance coverage and access to infusion-style visits, how severe and disruptive the hives are, and how the individual has responded to earlier steps. How long does chronic hives last is part of that conversation too, since chronic urticaria natural history varies enormously and a clinician weighs the likely duration of treatment against each option's monitoring burden. Tracking how to track chronic hives severity with a structured weekly score, rather than a general sense of better or worse, gives the clinician something concrete to judge whether a chosen treatment is actually working and worth continuing. Cost and insurance coverage often shape the decision as much as the clinical factors do, since an injectable biologic and an oral generic medication can look very different on a pharmacy bill or an insurance formulary, which is worth asking about directly alongside the medical conversation.

Common questions

Generally, yes, when both are reasonable options — omalizumab has stronger urticaria-specific trial evidence and is FDA-approved for this use, which is why most guidelines and clinicians reach for it first. Cyclosporine remains a real option when omalizumab isn't accessible, isn't tolerated, or hasn't worked well enough, not a lesser choice overall.

There's no fixed duration — it depends on how the individual case of chronic hives is progressing and how well a given treatment is working. Some people stay on a targeted therapy for months before stepping back down to simpler treatment once hives have been quiet for a sustained stretch, guided by a clinician reassessing on a set schedule.

No — omalizumab doesn't require the same routine lab monitoring of kidney function and blood pressure that cyclosporine does, since it works through a more targeted mechanism rather than suppressing the immune system broadly. Omalizumab does involve periodic injection visits and monitoring for reaction risk after each dose.

The strongest trial evidence for omalizumab is in chronic spontaneous urticaria, hives without an identifiable trigger, rather than chronic inducible urticaria, where a specific physical trigger sets hives off. Whether a targeted therapy is the right category of treatment for inducible hives is a separate conversation with a specialist, since managing the trigger itself is often part of that picture.

Both are generally started and monitored by a dermatologist or allergist experienced with chronic urticaria, given the monitoring each requires and the judgment involved in choosing between them. A primary care clinician is usually the right person to make that referral rather than start either treatment directly.

Related

Deciding about this?

A short, sourced overview to weigh with your clinician:

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When chronic hives need urgent, not just escalated, care

  • —Swelling of the lips, tongue, or throat, or any trouble breathing or swallowing
  • —Hives with dizziness, fainting, or a racing heart
  • —Wheals that hurt or burn rather than itch, bruise, or last longer than a day each, which can point to a different diagnosis than typical hives
  • —Fever, joint pain, or feeling generally unwell alongside the hives

Swelling of the throat or tongue, or trouble breathing or swallowing, is a medical emergency — call 911.

This article is general health information, not medical advice. It compares two treatment options for chronic hives in general terms but cannot decide which is right for an individual case. A dermatologist or allergist can weigh a person's full health history before choosing between them.

References

  1. 1.Maurer M, Rosén K, Hsieh HJ, et al. (2013). Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. New England Journal of Medicine. doi:10.1056/NEJMoa1215372 ✓Phase 3 randomized trial showing omalizumab improves itch and urticaria symptoms in patients with chronic idiopathic/spontaneous urticaria refractory to H1-antihistamines.
  2. 2.Bernstein JA, Lang DM, Khan DA, et al. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology. PMID 24766875 ✓Joint Task Force practice parameter describing the stepwise management of chronic urticaria, from second-generation antihistamines and dose escalation to add-on options for antihistamine-refractory disease.

2 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library